Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer's Disease and Affects Mice with Normal Aging

Frontiers in Pharmacology
Raquel Baeta-CorralLydia Giménez-Llort

Abstract

Coffee or caffeine has recently been suggested as prophylaxis for dementia. Although memory problems are hallmarks of Alzheimer's disease, this dementia is also characterized by neuropsychiatric symptoms called Behavioral and Psychological Symptoms of Dementia (BPSD). The impact of preventive/therapeutic strategies on both cognitive and non-cognitive symptoms can be addressed in the 3xTg-AD mice, since they exhibit cognitive but also BPSD-like profiles. Here, we studied the long-term effects of a low dose of caffeine in male 3xTg-AD mice and as compared to age-matched non-transgenic (NTg) counterparts with normal aging. Animals were treated (water or caffeine in drinking water) from adulthood (6 months of age) until middle-aged (13 months of age), that in 3xTg-AD mice correspond to onset of cognitive impairment and advanced stages, respectively. The low caffeine dosing used (0.3 mg/ml) was previously found to give a plasma concentration profile in mice roughly equivalent to that of a human coffee drinker. There were significant effects of caffeine on most behavioral variables, especially those related to neophobia and other anxiety-like behaviors, emotionality, and cognitive flexibility. The 3xTg-AD and NTg mice were differentl...Continue Reading

References

Mar 1, 1994·Journal of the Experimental Analysis of Behavior·K SilvermanR R Griffiths
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·B JohanssonB B Fredholm
Jul 9, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L Maia, A de Mendonça
Mar 19, 2005·Dementia and Geriatric Cognitive Disorders·Maristella PiccininniDomenico Inzitari
Mar 17, 2006·Pharmacology & Therapeutics·Louise A HorriganThomas J Connor
Oct 24, 2006·Neuroscience and Biobehavioral Reviews·L Giménez-LlortA Fernández-Teruel
Mar 31, 2007·Cell Death and Differentiation·B B Fredholm
Apr 2, 2008·Neurotoxicology and Teratology·Nika L Anderson, Robert N Hughes
Jan 23, 2009·Journal of Alzheimer's Disease : JAD·Marjo H EskelinenMiia Kivipelto
Jul 8, 2009·Journal of Alzheimer's Disease : JAD·Gary W ArendashHuntington Potter
Jul 8, 2009·Journal of Alzheimer's Disease : JAD·Chuanhai CaoHuntington Potter
Nov 27, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Paula M CanasRodrigo A Cunha
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·Ana Rita CostenlaAlexandre de Mendonça
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·Astrid Nehlig
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·Gary W Arendash, Chuanhai Cao
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·Marjo H Eskelinen, Miia Kivipelto
Feb 26, 2010·Journal of Alzheimer's Disease : JAD·Jiang-Fan ChenRongyuan Zheng
Jul 16, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Judit EspañaCarlos A Saura
Oct 29, 2010·International Journal of Alzheimer's Disease·Lydia Giménez-LlortCoral Sanfeliu
Feb 8, 2011·Journal of Alzheimer's Disease : JAD·Yoelvis García-MesaCoral Sanfeliu
Mar 24, 2011·Journal of Alzheimer's Disease : JAD·Sueli MarquesTiago Fleming Outeiro
Dec 14, 2011·Cancer Investigation·Hanna BesslerMeir Djaldetti
Dec 20, 2011·Neurobiology of Aging·Yoelvis García-MesaCoral Sanfeliu
Mar 21, 2012·Journal of Alzheimer's Disease : JAD·Chuanhai CaoGary W Arendash
Jul 25, 2012·Annals of the New York Academy of Sciences·Lydia Giménez-LlortMónica De la Fuente
Oct 23, 2013·Behavioural Brain Research·R Baeta-Corral, L Giménez-Llort
Oct 24, 2013·Journal of Alzheimer's Disease : JAD·Monica MarcheseBoris Sakic
Mar 5, 2014·Current Pharmaceutical Design·Lydia Giménez-LlortMónica De la Fuente
May 27, 2014·Behavioural Processes·Virginia Torres-Lista, Lydia Giménez-Llort
Jan 23, 2015·The International Journal of Neuropsychopharmacology·Adele RomanoTommaso Cassano

❮ Previous
Next ❯

Citations

Jan 8, 2019·Critical Reviews in Food Science and Nutrition·Muhammad SaeedSun Chao
May 20, 2020·British Journal of Pharmacology·Kenneth A JacobsonJens Carlsson
May 28, 2020·Frontiers in Pharmacology·Damiana ScuteriMaria Tiziana Corasaniti
Aug 21, 2018·Frontiers in Neuroscience·Lucrezia CellaiVictoria Gomez-Murcia
Oct 30, 2018·Frontiers in Neuroscience·Ross S ManciniDonald F Weaver
Feb 11, 2021·Nutrients·Piotr LondzinJoanna Folwarczna
Mar 3, 2021·European Journal of Pharmacology·Tayebeh NooriSamira Shirooie
May 18, 2021·Current Medical Research and Opinion·Chen Yiding, Huang Zhongyi

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA

Related Concepts

Related Feeds

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Cell Aging (Keystone)

This feed focuses on cellular aging with emphasis on the mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Aging Epidemiology

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.